AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05073224 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Straight Leg Raise Fatigue Task
Description: The protocol is similar to the ASLR test, except that the participant is instructed to maintain the elevated leg off the ground for as long as possible. A biofeedback air cuff will be placed under the participant's lumbopelvic region to assess movement of the spine/pelvis. The cuff will be inflated to 40 mm Hg, and the participant instructed to keep the needle as close to 40 mm Hg as possible throughout the test; no information will be provided on how to affect cuff pressure, but visual feedback of cuff pressure will be provided throughout the task. Ratings of perceived exertion (RPE) and pain will be obtained from participants every 30-60 seconds. Task failure will be defined as a heel height ≤10 cm or a change in cuff pressure ≥20 mm Hg. Both limbs will be tested, but in different sessions. The order of limb testing (dominant vs non-dominant) will be randomized and counter-balanced. Limb dominance will be self-reported.
Study NCT05073224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Straight Leg Raise Fatigue Task
Description: The protocol is similar to the ASLR test, except that the participant is instructed to maintain the elevated leg off the ground for as long as possible. A biofeedback air cuff will be placed under the participant's lumbopelvic region to assess movement of the spine/pelvis. The cuff will be inflated to 40 mm Hg, and the participant instructed to keep the needle as close to 40 mm Hg as possible throughout the test; no information will be provided on how to affect cuff pressure, but visual feedback of cuff pressure will be provided throughout the task. Ratings of perceived exertion (RPE) and pain will be obtained from participants every 30-60 seconds. Task failure will be defined as a heel height ≤10 cm or a change in cuff pressure ≥20 mm Hg. Both limbs will be tested, but in different sessions. The order of limb testing (dominant vs non-dominant) will be randomized and counter-balanced. Limb dominance will be self-reported.
Study NCT05073224 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower Extremity Strength Testing
Description: A straight leg raise maximal voluntary contraction (MVC) of each lower extremity an MVC of the hip extensors of the grounded limb will be performed in supine before and within 2 minutes of completing the ASLR fatigue task. The straight leg raise MVC will be performed with a custom-made load cell instrumented strength testing device, which consists of a rigid platform on which the participant will lie. At the foot of the device is a tower that houses 2 load cells connected to a lightly padded push plate.~The hip extension MVC will be performed on a force plate. Before the ASLR fatigue task, a minimum of 3 MVC trials will be performed for each muscle group, with a minimum of 1 minute rest between trials; the highest peak force will be considered the MVC. Only 1 MVC trial per muscle group will be performed following the ASLR Fatigue Task.
Study NCT05073224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower Extremity Strength Testing
Description: A straight leg raise maximal voluntary contraction (MVC) of each lower extremity an MVC of the hip extensors of the grounded limb will be performed in supine before and within 2 minutes of completing the ASLR fatigue task. The straight leg raise MVC will be performed with a custom-made load cell instrumented strength testing device, which consists of a rigid platform on which the participant will lie. At the foot of the device is a tower that houses 2 load cells connected to a lightly padded push plate.~The hip extension MVC will be performed on a force plate. Before the ASLR fatigue task, a minimum of 3 MVC trials will be performed for each muscle group, with a minimum of 1 minute rest between trials; the highest peak force will be considered the MVC. Only 1 MVC trial per muscle group will be performed following the ASLR Fatigue Task.
Study NCT05073224 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound imaging of abdominal wall
Description: Real time ultrasound will be used to assess inter-recti distance above and below the umbilicus. Participants will be assessed with B Mode images in supine at rest, in supine while lifting their head, and in supine while performing a straight leg raise. The Principle Investigator has training and experience in musculoskeletal ultrasound.
Study NCT05073224 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound imaging of abdominal wall
Description: Real time ultrasound will be used to assess inter-recti distance above and below the umbilicus. Participants will be assessed with B Mode images in supine at rest, in supine while lifting their head, and in supine while performing a straight leg raise. The Principle Investigator has training and experience in musculoskeletal ultrasound.
Study NCT05839067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care-HF
Description: Participants will be trained to use a 5-step problem-solving process based on the Theory of Social Problem-Solving (TSPS) to manage HF-related problems over 12-weeks. The core belief of TSPS is effective problem-solving requires a positive problem orientation (i.e., viewing problems as a challenge versus a threat) and elicits rational problem-solving versus avoidance or impulsivity/carelessness. Problem-solving follows from a positive problem orientation and involves accurate problem identification, generation of appropriate potential solutions, active decision-making, and solution implementation and evaluation. The goal of this intervention is to move participants toward a positive problem orientation and use of rational problem-solving strategies that support greater physical and mental health.
Study NCT04899011 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire about taste and salivary disturbance before surgery, 10 days, 4 months and 1 year after surgery.~Questionnaires include characteristics of taste disturbance, and specific impact on quality of life.
Study NCT04944927 — intervention group
Intervention type: OTHER
Intervention: Recording of clinical parameters and electrocardiogram parameters
Description: Retrospective recording of demographic information (age, sex, age at diagnosis), genetic information, cardiological information, pharmacological treatments, electrocardiogram data. All above data will be deidentified.
Study NCT06020768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the bed-head was raised to an angle of 0, 20, 30 and 45 degrees
Description: With each patient in the supine position, the bed-head was raised to an angle of 0, 20, 30 and 45 degrees without a pillow, and the haemodynamic parameters of central venous pressure, systolic and diastolic blood pressure, heart rate, breathing rate and peripheral oxygen saturation were recorded after 0 and 10 minutes.
Study NCT05375825 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery
Description: Cytoreductive surgery: minimally invasive (VATS/robotic) or open (thoracotomy)
Study NCT05375825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMB-100
Description: 1000 mcg/mL (DL1) post-operative dose as a single 90-minute normothermic intrathoracic perfusion using a closed circuit and roller pump with a heat exchanger following maximal cytoreductive surgery
Study NCT05375825 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Immunohistochemical Assay for Mesothelin
Description: Performed at screening to determine mesothelin expression; separate testing of tumor mesothelin expression will be assessed retrospectively in resected tumor tissues. The device is not diagnostic; protocol assessment of mesothelin expression status will only be used to help to increase the possibility that all persons enrolling on the study might derive benefit from therapy.
Study NCT05085327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ChapStick Lip Moisturizer Original
Description: Sunscreen lip balm.
Study NCT05085327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ChapStick Lip Moisturizer Mint
Description: Sunscreen lip balm.
Study NCT05085327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ChapStick Lip Moisturizer Black Cherry
Description: Sunscreen lip balm.
Study NCT05085327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPF Standard Sunscreen
Description: SPF Standard (7 percent \[%\] Padimate-O and 3% Oxybenzone)
Study NCT05305625 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: remote ischemic postcondioning
Description: remote ischemic postcondioning twice daily, for three consecutive days，the upper arm of the lighter paralyzed side was pressurized to 200mmHg, pressurized 5min and relaxed for 5 minutes for 4 cycles as a complete remote ischemic postcondioning
Study NCT05305625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard therapy
Description: received standardized treatment
Study NCT06389539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SBD111 medical food
Description: SBD111 medical food is a defined microbial assemblage (DMA) consisting of oligofructose and dried berry powder (prebiotics), a Pseudomonas fluorescens, a Lactobacillus brevis, a Leuconostoc mesenteroides, a Lactobacillus plantarum, and a Pichia kudriavzevii (yeast).
Study NCT06389539 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06211972 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OpiVenture
Description: OpiVenture, a targeted psychosocial intervention, complements opioid agonist therapy for opioid use disorder. Adapted from proven interventions like PreVenture, it unfolds over three sessions. Session one covers introductions, an ice-breaker, trait overview, strengths/limitations discussion, goal setting, and homework. Session two reviews homework, explores coping strategies, weighs alternatives, introduces hot thoughts, reviews trait-specific hot thoughts, and assigns homework. The concluding session involves reviewing homework, identifying personal hot thoughts, challenging them through a cognitive-behavioral exercise, applying insights to goal setting, and concluding with a wrap-up.
Study NCT06100185 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PeakSleep
Description: The PeakSleepTM is a constant current device which delivers stable stimulation as a function of the impedance measured across the electrodes (e.g. it varies voltage to produce a steady current). The device gradually ramps up the current as the impedance decreases during the stimulation session. The device uses stimulation amplitudes in the range of 100uA to 500uA at each electrode pair. Devices will be configured to deliver 100 stimulation trains over 30 minutes where each train is 6 pulses of 0.75Hz trapezoidal stimulation (each train lasts 8 seconds). The inter-train interval is 10 seconds leading to a total stimulation time of \<14 minutes with a maximum dose of 1mA (500uA per electrode pair).
Study NCT06100185 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham is delivered with the same devices which are alternatively configured to deliver a trivially low amplitude (e.g. 100uA) waveform of a different frequency (e.g. 25 Hz) for the same treatment duration. Beyond differences in amplitude and frequency of stimulation, devices will be operated in exactly the same way during sham treatment.
Study NCT05068102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765063
Description: BI 765063
Study NCT05068102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezabenlimab
Description: Ezabenlimab
Study NCT05068102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [89Zr]Zr- BI 765063
Description: \[89Zr\]Zr- BI 765063, specifically radiolabelled for immune-Positron Emission Tomography (PET)
Study NCT05068102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 770371
Description: BI 770371
Study NCT05068102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [89Zr]Zr- BI 770371
Description: \[89Zr\]Zr- BI 770371, specifically radiolabelled for immune-PET
Study NCT05728684 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM310
Description: CM310 Injection
Study NCT04973163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1823911
Description: BI 1823911
Study NCT05608200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib, sintilimab plus TACE
Description: Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd and sintilimab (200mg I.V. q3w) will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated. Treatment of sintilimab will last up to 24 months. Patients will be allowed to have lenvatilib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
Study NCT05608200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib plus TACE
Description: Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated. The interruption, dose reduction and discontinuation of lenvatinib depended on the presence and severity of toxicities according to the drug directions.
Study NCT04973163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1701963
Description: BI 1701963
Study NCT04973163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam - only administered in Part B (dose confirmation) of the Monotherapy Arm
Study NCT05791162 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood collection
Description: Collection of 3 blood tubes at inclusion and relapse (arm 1) or at inclusion, initiation of treatment and at 3 and 6 months post-diagnosis (arm 2)
Study NCT05791162 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Urine sample
Description: Collection of 20 cc of urine at inclusion and relapse (arm 1) or at inclusion, initiation of treatment and at 3 and 6 months post-diagnosis (arm 2) or at inclusion only (arm 3)
Study NCT06638099 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CGM Toolkit Prescriber Training
Description: A CGM prescription toolkit was created for prescribing clinicians and staff that includes written guidance on CGM eligibility criteria, instructions for screening patients for eligibility using EHR records and during healthcare visits, recommended provider documentation templates to address all required eligibility criteria for insurance coverage of CGM device and supplies (e.g., Medicare, Medicaid), sample scripts for communicating with patients about the purpose and use of CGM, and patient-level frequently asked questions (FAQs), including free resources available to learn more about CGM benefits, where/how to acquire CGM, and determining out-of-pocket costs. The toolkit will be introduced during a 20 minute initial training session and reinforced during a 10 minute booster training approximately one month after initial training
Study NCT05829564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: The individuals participating in the study will experience virtual reality.
Study NCT05829564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical mobilization
Description: The individuals participating in the study will be applied cervical mobilization techniques.
Study NCT05829564 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: exercise
Description: The individuals participating in the study will performed neck-specific exercises.
Study NCT05829564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: The individuals participating in the study will performed neck-specific exercises.
Study NCT05050383 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pharyngeal Manometry
Description: Catheters will be passed into the nose and advanced to the pharynx to measure airway pressures during drug-induced sleep.
Study NCT04658017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GARNET device
Description: Use of new filter in conjunction with standard of care dialysis.
Study NCT05050383 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Submental Ultrasound
Description: Ultrasound of airway soft tissues
Study NCT06261710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sonography in labour
Description: Using intrapartum sonography parameters in labour
Study NCT06433713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine IV
Description: They received IV infusion of 2 mg/kg per hour of lidocaine starting with skin incision, which was maintained until skin closure. This was done using a syringe pump with the calculated amount of lidocaine added to 50 ml of normal saline infused at a rate of 50 ml/hr.
Study NCT06433713 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% normal saline infusion
Study NCT04859296 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaporized placebo
Study NCT04859296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low CBG
Description: Vaporized CBG (5 mg)
Study NCT04859296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High CBG
Description: Vaporized CBG (15 mg)
Study NCT04859296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low THC
Description: Vaporized THC (5 mg)
Study NCT04859296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High THC
Description: Vaporized THC (15 mg)
Study NCT06036212 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic System
Description: Robotic assisted Unicompartmental Knee replacement (UKA)
Study NCT06036212 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Conventional
Description: Unicompartmental Knee Arthroplasty (UKA) with conventional approach and conventional manual instrumentation
Study NCT05780619 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial Doppler
Description: Measurement of resistance index on the middle cerebral artery (MCA) (index test) and the Holter (reference test). Patients will be randomized for order of tests
Study NCT06460207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI neurofeedback
Description: fMRI neurofeedback is a technique that allows individuals to observe real-time feedback of their brain activity as measured by fMRI scans. During a session, the participant lies inside an MRI scanner while their whole brain is scanned. This data is processed in real-time by a computer and then presented to the participant in the form of visual feedback. This feedback might be presented as a graph, a color-coded representation, or some other easily interpretable format. The participant is instructed to modulate their brain activity based on the feedback they receive. This can involve various mental strategies, such as focusing attention on specific thoughts, images, or sensations. Over repeated sessions, participants learn to consciously influence their brain activity based on the feedback they receive. Through trial and error, they discover which mental strategies are most effective for achieving their desired changes in brain activity.
Study NCT06380868 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravascular imaging-guided PCI
Description: Intravascular imaging including intravascular ultrasound or optical coherence tomography.
Study NCT06380868 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography-guided PCI group
Description: Deployment of a drug-eluting stent under angiography.
Study NCT05249374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Serum Albumin
Description: 10 g/bottle (20%, 50 mL)
Study NCT05260398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mightier Online Gameplay
Description: Mightier is a video-game-based biofeedback intervention that capitalizes on children's love of video games to increase emotional awareness and facilitate emotion regulation practice through heart rate (HR) control. Each family receives a Mightier Kit (Mighty Band heart rate monitor, dedicated Mightier tablet unless the family prefers to use their own device) and the Mightier App. Children wear a Mighty Band heart rate monitor on their arm while they play any one of 26+ games. As their heart rate rises the games become more difficult. For example, during a cooking game, smoke may appear on the screen and obscure the player's view. Children can either opt into an explicit cool down activity (deep breathing, progressive muscle relaxation, crossing the midline, or visualization) or cool down on their own. By simply playing Mightier, children are motivated to practice calming strategies in moments of challenge.
Study NCT05564754 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Feedback-controlled temperature device
Description: If core body temperature exceeds 37.7°C a feedback controlled-device will be used and set at 37.5°C.
Study NCT05564754 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High MAP
Description: A MAP target of >85mmHg will be used. Vasopressors will be titrated to this target during 36h.
Study NCT05564754 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deep sedation
Description: Deep sedation for at least 36h
Study NCT05249374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human serum albumin
Description: 10 g/bottle (20%, 50 mL)
Study NCT05559138 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT05013684 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Particle Repositioning Maneuver
Description: treatment with Particle Repositioning Maneuver
Study NCT06136793 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HomeStyles-China
Description: 2-arm \~10 week educational intervention
Study NCT06136793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HomeStyles-China
Description: 2-arm \~10 week educational intervention